Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06745323 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC

Name: A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC — clinical trial record (NCT06745323)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: DeLLphi-309

StatusActive, Not Recruiting

PhasePhase 2

SponsorAmgen

Started2025-02-26

View on ClinicalTrials.gov ↗

The primary objective of this study is to describe the antitumor activity of tarlatamab in participants with small cell lung cancer (SCLC).

Amendment history 2 changes detected by DataLookout

2026-08-18

Primary completion pushed: 2029-02-09 → 2029-05-10

2026-08-18

Completion pushed: 2029-02-09 → 2029-05-10

Trial Details

NCT Number	NCT06745323
Lead Sponsor	Amgen
Conditions	Small Cell Lung Cancer (SCLC)
Enrollment	252 participants
Start Date	2025-02-26
Primary Completion	2029-05-10 (estimated)
Study Completion	2029-05-10 (estimated)
Updated on ClinicalTrials.gov	2026-08-17